News|Articles|November 2, 2015

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-11-04-2015
  • Volume 11
  • Issue 11

FDA Extends Compliance Dates for Drug Dispensers

Citing compliance issues, FDA extends deadline for product tracing information requirements for dispensers to March 1, 2016.

FDA has issued a revised guidance document that extends a previously issued Compliance Policy for the Drug Supply Chain Security Act (DSCSA) from Nov. 1, 2015 to March 1, 2016 because some drug dispensers-primarily smaller, independent pharmacies and health systems-have expressed that they need additional time to work with partners on compliance issues.  

The DSCSA requires dispensers, primarily pharmacies, to comply with new requirements related to product tracing beginning July 1, 2015. In a Compliance Policy published on July 6, 2015, FDA stated that the agency did not intend to take action until Nov. 1, 2015 against dispensers that accepted ownership of product without receiving the product tracing information or who did not capture and maintain the product tracing information as required by the law. 

The most recent FDA guidance document, DSCSA Implementation: Product Tracing Requirements for Dispensers–Compliance Policy (Revised), issued on Oct. 28, 2015, extends this compliance date to March 1, 2016. FDA notes that the compliance policy does not extend to other requirements of the Federal Food, Drug, and Cosmetic Act, including those in section 582, such as verification related to suspect and illegitimate product (including quarantine, investigation, notification and recordkeeping) and requirements related to engaging in transactions only with authorized trading partners.

The guidance document is available on the FDA website.

Source:  US Food and Drug Administration

 

 

 


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Complying with International Pharmacopoeias
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.